Atrial fibrillation treatment using pulsed energy and an appendage closure
Part of Heart & circulation clinical trials.
This trial tests whether combining a pulsed-field ablation (a targeted heart rhythm treatment) with closing off the left atrial appendage can reduce atrial fibrillation risk. It may help people who need rhythm treatment and also want to lower future stroke risk by blocking a common clot-forming spot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have paroxysmal or persistent atrial fibrillation (not permanent atrial fibrillation).
- You’re an adult age 18 or older and can sign a consent form in writing.
- Your stroke risk score (CHADS2-VASc) is 2 or higher.
- You must be able to take mouth blood thinners (anticoagulants) for at least 3 months after the ablation.
- Your heart ultrasound test (TEE) must not show a clot in the left atrial appendage before the procedure or during it.
- You should not have had a prior left atrial appendage closure procedure, and you should be willing to have follow-up TEE checks after the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a heart procedure (catheter ablation) with a device to close the left atrial appendage (LAAO) is safer or better than blood thinners alone for frail patients 75 years or older with atrial fibrillation and high stroke risk. It aims to find a treatment that reduces stroke while lowering bleeding risks.
This trial tests a new type of heart procedure called pulsed field ablation to treat an irregular heartbeat (atrial fibrillation) in people who have already had a device placed to close off a part of the heart (left atrial appendage occlusion). The goal is to see if this safer ablation method can help control your heart rhythm.
This study tests if adding a special energy treatment (pulsed field ablation) to a standard heart pouch closure is safe and works better for people with persistent atrial fibrillation who have few symptoms but a high risk of stroke.
This trial combines two procedures at once: a pulsed field ablation to treat atrial fibrillation and a device implant to close the left atrial appendage to reduce stroke risk. It is designed for people in Asia who need both treatments and may benefit from having them together.
This trial tests a new method called pulsed field ablation to treat atrial fibrillation (AF), a type of irregular heartbeat. It aims to safely stop AF episodes by targeting specific areas in the heart, and may help people with paroxysmal (coming and going) or persistent AF who haven't had this procedure before.
This trial is for people who need both a special heart treatment called pulsed field ablation (FARAPULSE) and a device to close off a small pouch in the heart (WATCHMAN FLX Pro or WATCHMAN FLX) to prevent strokes. The study will see how well both procedures work when done together.
Hear when a new Combined Pulsed-field Ablation (PFA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.